Enyo Pharma SAS
Latest From Enyo Pharma SAS
The first half of 2018 appeared promising for the European biopharma sector, with multiple large investment funds promising cash to young, innovative companies in the region – a turnaround after years of life science firms suffering from a funding drought across Europe.
Freeline Therapeutics, I-Mab Biopharma, Kaleido Biosciences and Precision BioSciences raised more than $100m each, but Chinese start-ups continue to bring in some of this year's largest venture capital mega rounds, with $220m in Series C cash to fund development of immuno-oncology and inflammatory disease drug candidates.
Emerging Company Profile: ENYO Pharma has been around for barely four years, but it is already advancing its lead programs into Phase II trials in hepatitis B and NASH, and anticipates many more uses for its virology-based platform that will go way beyond treating virus infections.
Finance Watch: Pfizer Ventures' Dalton Makes Sense Of Neuroscience Focus Within New $600m VC Fund Commitment
Venture Capital Edition: Pfizer deprioritized neuroscience as an early R&D focus earlier this year, but will stay involved by spending 25% of the $600m added to its venture fund on neurology investments. Also, China VC investment keeps up fast pace and Alta Partners closes a new $130m health care fund.
- Drug Discovery Tools
- Large Molecule
- Therapeutic Areas
- Hepatic (Liver)
- Infectious & Viral Diseases
- Western Europe
- Parent & Subsidiaries
- Enyo Pharma SAS
- Senior Management
Jacky Vonderscher, PhD, CEO
Jonathan Lieber, CFO
Eric Meldrum, PhD, CSO
Nicolas Guyon-Gellin, MD, VP, Corp. Dev. & Strategy
Pietro Scalfaro, MD, CMO
- Contact Info
Enyo Pharma SAS
Phone: 4 37 70 02 19
BIOSERRA 1 Bâtiment, 60 ave Rockefeller
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.